A primer on recent developments in cancer immunotherapy, with a focus on neoantigen vaccines

Abstract

Cancer immunotherapy has now been conclusively shown to be capable of producing durable responses for a substantial number of patients. Adoptive cell transfer and checkpoint blockade therapies in particular both demonstrate that antigen-specific immune responses can be dramatically effective, even in previously refractory late stage disease. Such developments, together with advances in technology, have strongly encouraged revisiting the concept of neoantigen vaccines. Here we introduce basic ideas in the field to allow investigators from diverse backgrounds to understand these developments, grasp current issues, and contribute to further progress.

Keywords

Immunotherapy / cancer vaccine / immunoinformatics / precision medicine / combination therapy / theoretical models / systems biology

References

[1] Coley WBThe treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893..Clin Orthop Relat Res1991;(262):3-11

[2] Parish CRCancer immunotherapy: the past, the present and the future..Immunol Cell Biol2003;81:106-13

[3] Riera Romo MCastillo Ferrer CInnate immunity in vertebrates: an overview..Immunology2016;148:125-39PMC4863567

[4] Litman GWFugmann SDThe origins of vertebrate adaptive immunity..Nat Rev Immunol2010;10:543-53PMC2919748

[5] Xing YT-Cell tolerance: central and peripheral..Cold Spring Harb Perspect Biol2012;4:a006957PMC3367546

[6] Whitton JLAntigen Presentation..Berlin, Heidelberg: Springer;1998;

[7] van Endert PAntigen Processing: Methods and Protocols..Totowa, NJ: Humana Press;2013;PMC3691139

[8] Roche PAThe ins and outs of MHC class II-mediated antigen processing and presentation..Nat Rev Immunol2015;15:203-16

[9] Shah DK. T-cell development in thymus. British Society for Immunology. Available from:https://www.immunology.org/public-information/bitesized-immunology/immune-development/t-cell-development-in-thymus. [Last accessed on 29 Jul 2017]

[10] Crespo JWelling THZou WT cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment..Curr Opin Immunol2013;25:214-21PMC3636159

[11] Walker LSKConfusing signals: recent progress in CTLA-4 biology..Trends Immunol2015;36:63-70PMC4323153

[12] Manz BNPetit RSGroves JT-cell triggering thresholds are modulated by the number of antigen within individual T-cell receptor clusters..Proc Natl Acad Sci U S A2011;108:9089-94PMC3107331

[13] Reinherz ELαβ TCR-mediated recognition: relevance to tumor-antigen discovery and cancer immunotherapy..Cancer Immunol Res2015;3:305-12PMC4391277

[14] Meydan CSezerman OUPrediction of peptides binding to MHC class I and II alleles by temporal motif mining..BMC Bioinformatics2013;14 Suppl 2:S13PMC3549809

[15] Di Santo JPNatural killer cells: diversity in search of a niche..Nat Immunol2008;9:473-5

[16] Marsh SGEBodmer WFDupont BFernández-Viña MHoldsworth RLau MMach BMayr WRParham PSasazuki TSvejgaard ATiercy JMNomenclature for factors of the HLA system, 2010..Tissue Antigens2010;75:291-455PMC2848993

[17] Ghattaoraya GSGonzález-Galarza FFSantos EJMMcCabe AAlfirevic AJones ARA web resource for mining HLA associations with adverse drug reactions: HLA-ADR..Database (Oxford)2016;2016:baw069

[18] Robinson JHayhurst JDThe IPD-IMGT/HLA database -new developments in reporting HLA variation..Hum Immunol2016;77:233-7

[19] Arstila TPBaron VKanellopoulos JA direct estimate of the human αβ T cell receptor diversity..Science1999;286:958-61

[20] Davis MMFurman DSystems immunology: just getting started..Nat Immunol2017;18:725-32

[21] Britanova OVShugay MTurchaninova MABolotin DABogdanova EALebedev YBAge-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling..J Immunol2014;192:2689-98

[22] Qi QCheng YZhang DOlshen RABoyd SDDiversity and clonal selection in the human T-cell repertoire..Proc Natl Acad Sci U S A2014;111:13139-44PMC4246948

[23] Derhovanessian ELarbi AImmunity, ageing and cancer..Immun Ageing2008;5:11PMC2564902

[24] Elias RSira EImmunotherapy comes of age: immune aging & checkpoint inhibitors..J Geriatr Oncol2017;8:229-35

[25] Sewell AKWhy must T cells be cross-reactive?.Nat Rev Immunol2012;12:669-77

[26] Wucherpfenning KWMolecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein..Cell1995;80:695-705

[27] Cole DKDolton GSzomolay BTrimby AFuller ARossjohn JMiles JJWooldridge LSewell AKHotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity..J Clin Invest2016;126:2191-204PMC4887163

[28] Kumar ADynamical footprint of cross-reactivity in a human autoimmune T-cell receptor..Sci Rep2017;7:42496PMC5307354

[29] Harndahl MRoder GSørensen MBuus SPeptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity..Eur J Immunol2012;42:1405-16

[30] Yager EJLanzer KWoodland DLAge-associated decline in T cell repertoire diversity leads to holes in the repertoire and impaired immunity to influenza virus..J Exp Med2008;205:711-23PMC2275391

[31] Wölfl MMosbruger TLi HRay SCSidney JAllen TKavanagh DGGreenberg PDHepatitis C virus immune escape via exploitation of a hole in the T cell repertoire..J Immunol2008;181:6435-46PMC2742502

[32] Vatti APacheco YAnaya JMOriginal antigenic sin: a comprehensive review..J Autoimmun2017;83:12-21

[33] Joffre OPSavina ACross-presentation by dendritic cells..Nat Rev Immunol2012;12:557-69

[34] Fehres CMGarcia-Vallejo JJUnderstanding the biology of antigen cross-presentation for the design of vaccines against cancer..Front Immunol2014;5:149PMC3986565

[35] Zhu JCD4 T cells: fates, functions, and faults..Blood2008;112:1557-69PMC2518872

[36] Caza TFunctional and phenotypic plasticity of CD4+ T cell subsets..Biomed Res Int2015;2015:521957PMC4637038

[37] van de Berg PJten Berge IJCytotoxic human CD4+ T cells..Curr Opin Immunol2008;20:339-43

[38] Takeuchi ACD4 CTL, a cytotoxic subset of CD4+ T cells, their differentiation and function..Front Immunol2017;8:194PMC5321676

[39] Ley KThe second touch hypothesis: T cell activation, homing and polarization. version 2..F1000 Research2014;3:37

[40] Crome SQLopez-Verges SMartin BJohnson DJPniak MMilea AKatz SRClarke BALang PAPugh TJOhashi PSA distinct innate lymphoid cell population regulates tumor-associated T cells..Nat Med2017;23:368-75

[41] Hanahan DThe hallmarks of cancer..Cell2000;100:57-70

[42] Flavahan WABernstein BEEpigenetic plasticity and the hallmarks of cancer..Science2017;357:eaal2380

[43] Thomas FFort PDaoust SGrunau CMitta GRousset FAssenat EMissé DBilly FDelhommeau FItzykson RFava FLepoutre TDulic VBlache PVignal EPerthame BVolpert VHibner UApplying ecological and evolutionary theory to cancer: a long and winding road..Evol Appl2013;6:1-10PMC3567465

[44] Davis ANavin NTumor evolution: linear, branching, neutral or punctuated?.Biochim Biophys Acta2017;1867:151-61

[45] Paguirigan ALMeshinchi SMaley CSingle-cell genotyping demonstrates complex clonal diversity in acute myeloid leukemia..Sci Transl Med2015;7:281re2PMC4405099

[46] Sun RSottoriva AHarpak AFischer JMCurtis CBetween-region genetic divergence reflects the mode and tempo of tumor evolution..Nat Genet2017;49:1015-24PMC5643198

[47] Aktipis CAJohnson KAMaley CCOverlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research..PLoS One2011;6:e26100PMC3219640

[48] Campisi JAging, tumor suppression and cancer: high wire-act!.Mech Ageing Dev2005;126:51-8

[49] Weinberg RAThe biology of cancer..Second edition. New York: Garland Science, Taylor & Francis Group;2014;

[50] Abbas AKPillai SCellular and molecular immunology..Philadelphia, PA: Elsevier Saunders;2015;

[51] Rezaei NCancer Immunology..Berlin, Heidelberg: Springer Berlin Heidelberg;2015;

[52] Sell SCancer immunotherapy: breakthrough or "deja vu, all over again"?.Tumor Biol2017;39:1010428317707764

[53] Korman AJAllison JPCheckpoint blockade in cancer immunotherapy..Adv Immunol2006;90:297-339

[54] Palucka KCancer immunotherapy via dendritic cells..Nat Rev Cancer2012;12:265-77PMC3433802

[55] Gardner THahn NMSipuleucel-T (Provenge) autologous vaccine approved for treatment of men with asymptomatic or minimally symptomatic castrate-resistant metastatic prostate cancer..Hum Vaccines Immunother2012;8:534-9

[56] Rosenberg SAAdoptive cell transfer as personalized immunotherapy for human cancer..Science2015;348:62-8

[57] June CHPrinciples of adoptive T cell cancer therapy..J Clin Invest2007;117:1204-12PMC1857246

[58] Gross GEshhar ZExpression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity..Proc Natl Acad Sci U S A1989;86:10024-8PMC298636

[59] Longoria TCImmunotherapy in endometrial cancer - an evolving therapeutic paradigm..Gynecol Oncol Res Pract2015;2:11PMC4881063

[60] Page DBDaniyan ASmith EFriedman CFunt SOverwijk WWCallahan MKTumor immunology and cancer immunotherapy: summary of the 2014 SITC primer..J Immunother Cancer2015;3:25PMC4469248

[61] van Rooij NPhilips DToebes Mvan Dijk LJHilkmann HNieuwland MKerkhoven RMHaanen JBSchumacher TNTumor exome analysis reveals neoantigen-specific t-cell reactivity in an ipilimumab-responsive melanoma..J Clin Oncol2013;31:e439-42PMC3836220

[62] Hoos AJanetzki SIbrahim RHumphrey ROld LImproved endpoints for cancer immunotherapy trials..J Natl Cancer Inst2010;102:1388-97PMC2943524

[63] Bates SEBalasubramaniam SLoRusso PMAdvancing clinical trials to streamline drug development..Clin Cancer Res2015;21:4527-35

[64] Bhatt DLAdaptive designs for clinical trials..N Engl J Med2016;375:65-74

[65] Kato SWalavalkar VSharabi AHyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate..Clin Cancer Res2017;23:4242-50

[66] Tedeschi B. Cancer researchers worry immunotherapy may hasten growth of tumors in some patients. Available from: https://www.statnews.com/2017/04/03/immunotherapy-cancer-tumor-growth/. [Last accessed on 15 Dec 2017]

[67] Galon JMarincola FMThurin MZlobec IBifulco CTatangelo FKreiter SDelrio PAsslaber MMasucci GVVidal-Vanaclocha FGnjatic SHuber COttensmeier CLaghi LOhashi PSClarke BAKawakami YOkuno KO'Donnell-Tormey JPawelec GHawkins RLundqvist AOgino SWaring PTorigoe TPatel PSPalmqvist RWang YKopetz STrinchieri GAscierto PACancer classification using the Immunoscore: a worldwide task force..J Transl Med2012;10:205PMC3554496

[68] Gnjatic SBrunet LRDisis MLHakansson LGKaranikas VKirkwood JMSchendel DJWigginton JMIdentifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy..J Immunother Cancer2017;5:44PMC5432988

[69] Zitvogel LSmyth MJMechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance..Immunity2013;39:74-88

[70] O'Donnell JSTeng MWLPI3K-AKT-mTOR inhibition in cancer immunotherapy, redux..Semin Cancer Biol2017;

[71] Casey SCFelsher DWMYC: master regulator of immune privilege..Trends Immunol2017;38:298-305

[72] Bracci LSistigu AImmune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer..Cell Death Differ2014;21:15-25PMC3857622

[73] Tey SKAdoptive T-cell therapy: adverse events and safety switches..Clin Transl Immunol2014;3:e17PMC4232067

[74] Bertrand ABarnetche TSchaeverbeke TImmune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis..BMC Med2015;13:211PMC4559965

[75] Villadolid JImmune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities..Transl Lung Cancer Res2015;4:560-75PMC4630514

[76] Ott PAKeskin DBSun JZhang WGiobbie-Hurder AChen CCarter TALieb DJGjini ELane WJNellaiappan KDaley HBuchbinder EIHarden MGabriel SBarouch DHGetz GNeuberg DLander ESHacohen NAn immunogenic personal neoantigen vaccine for patients with melanoma..Nature2017;547:217-21PMC5577644

[77] Pappalardo FMotta SCancer vaccines: state of the art of the computational modeling approaches..Biomed Res Int2013;2013:106407PMC3591114

[78] Andor NJi HPGenomic instability in cancer: teetering on the limit of tolerance..Cancer Res2017;77:2179-85

[79] Coulie PGvan der Bruggen PTumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy..Nat Rev Cancer2014;14:135-46

[80] Guo CSubjeck JRFisher PBTherapeutic cancer vaccines: past, present, and future..Adv Cancer Res2013;119:421-75PMC3721379

[81] Melief CJMArens Rvan der Burg SHTherapeutic cancer vaccines..J Clin Invest2015;125:3401-12PMC4588240

[82] Gubin MMMardis ERTumor neoantigens: building a framework for personalized cancer immunotherapy..J Clin Invest2015;125:3413-21PMC4588307

[83] Slovin SFRagupathi GCarbohydrate vaccines as immunotherapy for cancer..Immunol Cell Biol2005;83:418-28

[84] Neefjes JA peptide's perspective on antigen presentation to the immune system..Nat Chem Biol2013;9:769-75

[85] Melief CJMImmunotherapy of established (pre)malignant disease by synthetic long peptide vaccines..Nat Rev Cancer2008;8:351-60

[86] Kumai THarabuchi YPeptide vaccines in cancer—old concept revisited..Curr Opin Immunol2017;45:1-7

[87] Li LPetrovsky NThe future of human DNA vaccines..J Biotechnol2012;162:171-82PMC3511659

[88] Sayour EJManipulation of innate and adaptive immunity through cancer vaccines..J Immunol Res2017;2017:3145742

[89] Kramps TeditorsRNA Vaccines..New York, NY: Springer New York;2017;PMC5737050

[90] Ulmer JBGeall ARNA-based vaccines..Vaccine2012;30:4414-8

[91] Beitelshees MPfeifer BAEnhancing vaccine effectiveness with delivery technology..Curr Opin Biotechnol2016;42:24-9PMC5233322

[92] Yang YLin ZChen DChen YAttenuated listeria monocytogenes as a cancer vaccine vector for the delivery of CD24, a biomarker for hepatic cancer stem cells..Cell Mol Immunol2014;11:184-96PMC4003383

[93] Cawood RWong SLBeadle SFisher KDRecombinant viral vaccines for cancer..Trends Mol Med2012;18:564-74

[94] Swartz MAHubbell JAEngineering approaches to immunotherapy..Sci Transl Med2012;4:148rv9

[95] Mehta NKIrvine DJEngineering new approaches to cancer vaccines..Cancer Immunol Res2015;3:836-43PMC4527881

[96] Francis DMProgress and opportunities for enhancing the delivery and efficacy of checkpoint inhibitors for cancer immunotherapy..Adv Drug Deliv Rev2017;114:33-42PMC5581991

[97] Kirpach JEpitopes..2015;Chichester, UKJohn Wiley & Sons, Ltd1-11

[98] Backert LImmunoinformatics and epitope prediction in the age of genomic medicine..Genome Med2015;7:119PMC4654883

[99] Segal NHPeggs KSKinzler KWAllison JPEpitope landscape in breast and colorectal cancer..Cancer Res2008;68:889-92

[100] Nielsen MLund OThe role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage..Immunogenetics2005;57:33-41

[101] Snyder AImmunogenic peptide discovery in cancer genomes..Curr Opin Genet Dev2015;30:7-16

[102] Vita RGreenbaum JAClark JDWheeler DKHix DPeters BThe immune epitope database (IEDB) 3.0..Nucleic Acids Res2015;43:D405-12PMC4384014

[103] Olsen LRLin HBrusic VTANTIGEN: a comprehensive database of tumor T cell antigens..Cancer Immunol Immunother2017;66:731-5

[104] Lund OLundegaard CNielsen MBioinformatics identification of antigenic peptide: predicting the specificity of major MHC class I and II pathway players..In: van Endert P, editor.2013;Antigen processingmethods and protocols. Humana Press, Totowa, NJ247-60

[105] Bjerregaard AMHadrup SREklund ACMuPeXI: prediction of neo-epitopes from tumor sequencing data..Cancer Immunol Immunother2017;66:1123-30

[106] Schubert BMohr CKohlbacher OImmunoNodes - graphical development of complex immunoinformatics workflows..BMC Bioinformatics2017;18:242PMC5422934

[107] Kobayashi HSong YCelis EDefining promiscuous MHC class II helper T-cell epitopes for the HER2/neu tumor antigen..Cancer Res2000;60:5228-36

[108] Stern LJThe melting pot of the MHC II peptidome..Curr Opin Immunol2016;40:70-7PMC4884503

[109] Hudrisier DPeptide-major histocompatibility complex class I complex: from the structural and molecular basis to pharmacological principles and therapeutic applications..In: Whitton JL, editor. Antigen presentation.1998;Berlin, HeidelbergSpringer75-97

[110] Faro JMolina-París CA unifying mathematical framework for experimental TCR-pMHC kinetic constants..Sci Rep2017;7:46741PMC5405415

[111] Yarchoan MLutz ERJaffee EMTargeting neoantigens to augment antitumour immunity..Nat Rev Cancer2017;17:209-22

[112] Schumacher TNNeoantigens in cancer immunotherapy..Science2015;348:69-74

[113] Yadav MPhung QTTanguay JFranci CFritsche JModrusan ZLill JRPredicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing..Nature2014;515:572-6

[114] Kowalewski DJBackert LKahn SSalih HRStevanovic SHLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)..Proc Natl Acad Sci U S A2015;112:E166-75PMC4299203

[115] Bassani-Sternberg MKlar RSinitcyn PStraub MSlotta-Huspenina JMartignoni MEHein RPeschel CCox JKrackhardt AMDirect identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry..Nat Commun2016;7:13404PMC5121339

[116] Bentzen AKLyngaa RRamskov SSuch LMcGranahan NStraten PTSvane IMQuezada SAEklund ACLarge-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes..Nat Biotechnol2016;34:1037-45

[117] Bunse LSahm FOezen IGonzalez MOsswald MWiestler BHerold-Mende CWick WProximity ligation assay evaluates IDH1R132H presentation in gliomas..J Clin Invest2015;125:593-606

[118] Schumacher TPusch SWiestler BMenn OOezen IKeil MRauschenbach KVogler ITrautwein NOkun JRiemer ABFriese MAvon Deimling APlatten MA vaccine targeting mutant IDH1 induces antitumour immunity..Nature2014;512:324-7

[119] Scheikl-Gatard TLemonnier FIdentification of new MUC1 epitopes using HLA-transgenic animals: implication for immunomonitoring..J Transl Med2017;15:154PMC5499006

[120] Schmidt JDojcinovic DCoukos GIn silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes..J Biol Chem2017;292:11840-9

[121] Gros ATran ERobbins PFPrickett TDCrystal JSTrebska-McGowan KYang JCProspective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients..Nat Med2016;22:433-8

[122] Tsherniak AMontgomery PGKryukov GGill SPantel SMeyers RMGoodale AJiang GGerath WFJMerkel EGarraway LAGolub TRHahn WCDefining a cancer dependency map..Cell2017;170:564-76.e16

[123] Uhlen MLee SFagerberg LBenfeitas RLiu ZSanli KOksvold PHober SMattsson JBrunnström HSjöblom TDjureinovic DLindskog CPonten FA pathology atlas of the human cancer transcriptome..Science2017;357:eaan2507

[124] Van Waes CUrban JLSchreiber HImmunodominant deters the response to other tumor antigens thereby favoring escape: prevention by vaccination with tumor variants selected with cloned cytolytic T cells in vitro..Tissue Antigens1996;47:399-407

[125] Kim ADeterminants of immunodominance for CD4 T cells..Curr Opin Immunol2015;34:9-15PMC4444386

[126] Macdonald IKHunt LCarroll AVGraham SPMorrison WIEllis SAMHC class I bound to an immunodominant theileria parva epitope demonstrates unconventional presentation to T cell receptors..PLoS Pathog2010;6:e1001149PMC2954893

[127] Hunt JDJackson DCAntigenic competition..Chichester, UK: John Wiley & Sons, Ltd;2001;

[128] Lund AWThe good and bad of T cell promiscuity..Sci Transl Med2016;8:341ec88

[129] Palmowski MDunbar RPThe use of HLA class I tetramers to design a vaccination strategy for melanoma patients..Immunol Rev2002;188:155-63

[130] Slingluff CLThe present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination?.Cancer J2011;17:343-50PMC3204371

[131] Kumai THarabuchi YCancer immunotherapy: moving forward with peptide T cell vaccines..Curr Opin Immunol2017;47:57-63

[132] Baxevanis CNTsitsilonis OESotiriadou RTumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor..J Immunol2000;164:3902-12

[133] Nakanishi YGerard CCD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help..Nature2009;462:510-3PMC2789415

[134] Sun ZMeng FLiu BMHC class II restricted neoantigen: a promising target in tumor immunotherapy..Cancer Lett2017;392:17-25

[135] Platten MCancer immunotherapy: exploiting neoepitopes..Cell Res2015;25:887-8PMC4528051

[136] Quezada SAPeggs KSVider JBlasberg RMuranski PRestifo NPTumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts..J Exp Med2010;207:637-50PMC2839156

[137] Tran EGros ALu YCWunderlich JRHogan KParkhurst MRRosenberg SACancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer..Science2014;344:641-5

[138] Sahin UMiller MSimon PBukur VLuxemburger UOmokoko TAlbrecht CKuhn ANHeesch SMüller FVogler IAttig SBreitkreuz ASuchan MHohberger ADiekmann JWaksmann OWitt MRothermel ALanger DDiken MNemecek RGrabbe SUtikal JLoquai CPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer..Nature2017;547:222-6

[139] Kreiter Svan de Roemer NLöwer MBoegel SVascotto FTadmor ADHuber CSahin UMutant MHC class II epitopes drive therapeutic immune responses to cancer..Nature2015;520:692-6PMC4838069

[140] Young MRICancer immunology with a focus on understudied cancers as targets for immunotherapy..Int J Mol Sci2017;18:E127PMC5297761

[141] Baxevanis CNPerez SAProstate cancer vaccines: the long road to clinical application..Cancer Immunol Immunother2015;64:401-8

[142] Roszik JHess KRJoon AYKarpinets TVBaladandayuthapani VWargo JAForget MAChen JQEterovic AKMills GBRadvanyi LGFutreal PALazar AJDavies MANovel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set..BMC Med2016;14:168PMC5078889

[143] Campesato LFJimenez LSabbaga JReis LFCamargo AAComprehensive cancer-gene panels can be used to estimate mutational load and predict clinical benefit to PD-1 blockade in clinical practice..Oncotarget2015;6:34221-7PMC4741447

[144] Alexandrov LBWedge DCBehjati SBignell GRBorg ABoyault SButler APDavies HREils RFoekens JAHosoda FIlicic TImielinski MJones DTKnappskog SLakhani SRMartin SNakamura HPajic MParadiso APuente XSRamakrishna MRichter JSchlesner MSpan PNTotoki YValdés-Mas Rvan 't Veer LWaddell N Signatures of mutational processes in human cancer..Nature2013;500:415-21PMC3776390

[145] Le DTSmith KNBartlett BRLu SWilt CWong FRucki AADonehower RFisher GALee JJDuffy AGEyring ADJoe AHoldhoff MCope LZhou SArmstrong DKFader ANHousseau FXiao NPapadopoulos NEshleman JRAnders RAMismatch repair deficiency predicts response of solid tumors to PD-1 blockade..Science2017;357:409-13PMC5576142

[146] Kloor Mvon Knebel Doeberitz MImmune evasion of microsatellite unstable colorectal cancers..Int J Cancer2010;127:1001-10

[147] Queirolo PAtypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: a systematic review..Cancer Treat Rev2017;59:71-8

[148] Anagnostou VForde PMBhattacharya RZhang TPhallen JHruban CRodgers KKang HGeorgiades CIllei PGabrielson EZahnow CAScharpf RBKarchin RVelculescu VEEvolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer..Cancer Discov2017;7:264-76

[149] Gulley JLPachynski RSheikh NADrake CGRole of antigen spread and distinctive characteristics of immunotherapy in cancer treatment..J Natl Cancer Inst2017;109

[150] Seliger BMolecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies..HLA2016;88:213-20

[151] Khanna RTumour surveillance: missing peptides and MHC molecules..Immunol Cell Biol1998;76:20-6

[152] Thor Straten PTargetless T cells in cancer immunotherapy..J Immunother Cancer2016;4:23PMC4835921

[153] Mahmoud FMakhoul IWong HKShalin SImmune surveillance in melanoma: from immune attack to melanoma escape and even counterattack..Cancer Biol Ther2017;18:451-69

[154] Gajewski TFZha YZheng YSpranger SCancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment..Curr Opin Immunol2013;25:268-76

[155] Dilek NBlancho GMyeloid-derived suppressor cells: mechanisms of action and recent advances in their role in transplant tolerance..Front Immunol2012;3:208PMC3398399

[156] Corthay AHow do regulatory T cells work?.Scand J Immunol2009;70:326-36PMC2784904

[157] Yang LTumor-associated macrophages: from basic research to clinical application..J Hematol Oncol2017;10:58PMC5329931

[158] Joyce JAT cell exclusion, immune privilege, and the tumor microenvironment..Science2015;348:74-80

[159] Spranger SHorton BTumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy..Cancer Cell2017;31:711-23.e4

[160] Buck MDKaech SMMetabolic instruction of immunity..Cell2017;169:570-86

[161] Chang C-HEmerging concepts of T cell metabolism as a target of immunotherapy..Nat Immunol2016;17:364-8PMC4990080

[162] Schietinger AKrisnawan VEDelrow JJLauer PKnoblaugh SESchell TDGreenberg PDTumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis..Immunity2016;45:389-401PMC5119632

[163] Schietinger ATolerance and exhaustion: defining mechanisms of T cell dysfunction..Trends Immunol2014;35:51-60PMC3946600

[164] Quezada SASimpson TRShifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication..Immunol Rev2011;241:104-18PMC3727276

[165] Waldhauer INK cells and cancer immunosurveillance..Oncogene2008;27:5932-43

[166] Marcus AThompson TWArdolino MWang LRaulet DHRecognition of tumors by the innate immune system and natural killer cells..Adv Immunol2014;122:91-128PMC4228931

[167] Dahlberg CIMChrobok MAlici ENatural killer cell-based therapies targeting cancer: possible strategies to gain and sustain anti-tumor activity..Front Immunol2015;6:605PMC4663254

[168] Morvan MGNK cells and cancer: you can teach innate cells new tricks..Nat Rev Cancer2016;16:7-19

[169] Ferlazzo GCross-talks between natural killer cells and distinct subsets of dendritic cells..Front Immunol2014;5:159PMC3989561

[170] Cai XGewe MMDrescher CWSpies TControl of tumor initiation by NKG2D naturally expressed on ovarian cancer cells..Neoplasia N Y N2017;19:471-82PMC5429243

[171] Bruno AAlbini AA think tank of TINK/TANKs: tumor-infiltrating/tumor-associated natural killer cells in tumor progression and angiogenesis..J Natl Cancer Inst2014;106:dju200PMC4344546

[172] Dammeijer Fvan Eijck CHJAerts JGJVRationally combining immunotherapies to improve efficacy of immune checkpoint blockade in solid tumors..Cytokine Growth Factor Rev2017;36:5-15

[173] Chen DSOncology meets immunology: the cancer-immunity cycle..Immunity2013;39:1-10

[174] Accolla RSOptimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines..J Transl Med2012;10:154PMC3478985

[175] Seliger BFerrone SHLA class II antigen-processing pathway in tumors: molecular defects and clinical relevance..Oncoimmunology2017;6:e1171447

[176] Ehlers MHautzel HReis ACAllelein SSchmid CEpitope-specific antitumor immunity suppresses tumor spread in papillary thyroid cancer..J Clin Endocrinol Metab2017;102:2154-61

[177] Vesely MDCancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy..Ann N Y Acad Sci2013;1284:1-5PMC3648872

[178] Zurrida SArnone PDel Castillo ASemenkiw METhe changing face of mastectomy (from mutilation to aid to breast reconstruction)..Int J Surg Oncol2011;2011:980158

[179] Dittmer JMechanisms governing metastatic dormancy in breast cancer..Semin Cancer Biol2017;44:72-82

[180] Benson JRThe TNM staging system and breast cancer..Lancet Oncol2003;4:56-60

[181] Weichselbaum RROligometastases revisited..Nat Rev Clin Oncol2011;8:378-82

[182] Sosa MSAguirre-Ghiso JAMechanisms of disseminated cancer cell dormancy: an awakening field..Nat Rev Cancer2014;14:611-22PMC4230700

[183] Eyles JWang XPrakash CTan TGOng LCKato MChow PAbastado JPTumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma..J Clin Invest2010;120:2030-9PMC2877955

[184] Romero IGarcia-Lora AMMetastases in immune-mediated dormancy: a new opportunity for targeting cancer..Cancer Res2014;74:6750-7

[185] Manjili MHTumor dormancy and relapse: from a natural byproduct of evolution to a disease state..Cancer Res2017;77:2564-9

[186] Barkan DPrevention of conversion of tumor dormancy into proliferative metastases..In: Cote RJ, Datar RH, editors. Circulating tumor cells. Current cancer research.2016;New York, NYSpringer New York121-37

[187] Whiteside TLRodriguez-Ruiz MEMelero IEmerging opportunities and challenges in cancer immunotherapy..Clin Cancer Res2016;22:1845-55PMC4943317

[188] Hoos ADevelopment of immuno-oncology drugs—from CTLA4 to PD1 to the next generations..Nat Rev Drug Discov2016;15:235-47

[189] Sharma PImmune checkpoint targeting in cancer therapy: toward combination strategies with curative potential..Cell2015;161:205-14

[190] Hucl TKern SEDistinguishing rational from irrational applications of pharmacogenetic synergies from the bench to clinical trials..Cell Cycle2007;6:1336-41

[191] Khong HAdjuvants for peptide-based cancer vaccines..J Immunother Cancer2016;4:56PMC5028954

[192] Saxena MTurbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines..Curr Opin Immunol2017;47:35-43

[193] Circelli LBuonaguro FMUse of adjuvants for immunotherapy..Hum Vaccines Immunother2017;13:1774-7

[194] Temizoz BIshii KJVaccine adjuvants as potential cancer immunotherapeutics..Int Immunol2016;28:329-38PMC4922024

[195] Hodi FSPavlick ACGrossmann KFLinette GPGiguere JKShaheen MMinor DRTaylor MHHorak CJiang JPostow MACombined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial..Lancet Oncol2016;17:1558-68

[196] Wu YJiang MJia KShang YJiang KThe clinical value of combination of immune checkpoint inhibitors in cancer patients: a meta-analysis of efficacy and safety..Int J Cancer2017;141:2562-70

[197] Schadendorf DHodi FSGonzalez RGrob JJLao CDRobert CMcDermott DBhore RPostow MAEfficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials..J Clin Oncol2017;35:3807-14

[198] Emens LADarcy PKEggermont AMMSeliger BCancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape..Eur J Cancer2017;81:116-29

[199] Dunn JEpigenetics and immunotherapy: the current state of play..Mol Immunol2017;87:227-39

[200] Probst POxenius ARitz DNeri DSarcoma eradication by doxorubicin and targeted TNF relies upon CD8+ T-cell recognition of a retroviral antigen..Cancer Res2017;77:3644-54PMC5557340

[201] Fessler JLThe microbiota: a new variable impacting cancer treatment outcomes..Clin Cancer Res2017;23:3229-31

[202] Li CXShi LLin QBYang MHuang JD"Obligate" anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice..Oncol Lett2017;13:177-83PMC5245073

[203] Mahoney KMFreeman GJCombination cancer immunotherapy and new immunomodulatory targets..Nat Rev Drug Discov2015;14:561-84

[204] Jaini RCohen PATuohy VKCombination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy..Int J Cancer2014;134:1695-705PMC3947113

[205] Albiges LEscudier BGeorge DLam TMulders PPowles TBex AA systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer..Eur Urol2015;67:100-10

[206] Moher DSchulz KFGøtzsche PCElbourne DAltman DGCONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials..J Clin Epidemiol2010;63:e1-37

[207] Simon RDevelopment and validation of biomarker classifiers for treatment selection..J Stat Plan Inference2008;138:308-20PMC2344143

[208] Gridelli CBarberis MCasaluce FTroncone GPredictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology..Transl Lung Cancer Res2017;6:373-86PMC5504112

[209] Altman DGSauerbrei WReporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration..PLoS Med2012;9:e1001216PMC3362085

[210] Sekula PAltman DGDid the reporting of prognostic studies of tumour markers improve since the introduction of REMARK guideline? A comparison of reporting in published articles..PLoS One2017;12:e0178531PMC5470677

[211] Stroncek DFCannarile MAGreten TFKaufman DRKorangy FMarincola FSiebert JCSeliger BSystematic evaluation of immune regulation and modulation..J Immunother Cancer2017;5:21PMC5359947

[212] Haris MHariharan HJohnson LAMolecular imaging biomarkers for cell-based immunotherapies..J Transl Med2017;15:140PMC5477274

[213] Spitzer MHReticker-Flynn NEMadhireddy DGherardini PFChabon JFong LEngleman EGSystemic immunity is required for effective cancer immunotherapy..Cell2017;168:487-502.e15

[214] Loo KMahuron KPauli MLNosrati AChen LLevine LSAlgazi APRosenblum MDPartially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy..JCI Insight2017;2:93433PMC5518562

[215] Kirsch IRobins HT-cell receptor profiling in cancer..Mol Oncol2015;9:2063-70PMC5528728

[216] Gros AYao XTurcotte SWunderlich JRFarid SHanada KDarko SYang JCPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors..J Clin Invest2014;124:2246-59PMC4001555

[217] Robert LWang XHomet BMok SCochran AJKoya RCRobins HCTLA4 blockade broadens the peripheral t-cell receptor repertoire..Clin Cancer Res2014;20:2424-32PMC4008652

[218] Akyüz NStein AMährle TGoekkurt EHaalck TAsemissen AMRadloff JKrohn-Grimberghe ABinder MT-cell diversification reflects antigen selection in the blood of patients on immune checkpoint inhibition and may be exploited as liquid biopsy biomarker..Int J Cancer2017;140:2535-44

[219] Dziubianau MKuchenbecker LStervbo UNickel PRobinson PNVolk HDReinke PTCR repertoire analysis by next generation sequencing allows complex differential diagnosis of T cell-related pathology..Am J Transplant2013;13:2842-54

[220] Rosati ELiaskou EKarlsen THOverview of methodologies for T-cell receptor repertoire analysis..BMC Biotechnol2017;17:61PMC5504616

[221] Madi AShifrut EGreenstein EArnon TSinger ASun PDFriedman NT cell receptor repertoires of mice and humans are clustered in similarity networks around conserved public CDR3 sequences..Elife2017;6:e22057PMC5553937

[222] Emerson ROVignali MHu JKDesmarais CCarlson CSRieder MImmunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire..Nat Genet2017;49:659-65

[223] Garner JPWeber EMPritchett-Corning KRIntroducing Therioepistemology: the study of how knowledge is gained from animal research..Lab Anim (NY)2017;46:103-13

[224] Klevorn LEAdapting cancer immunotherapy models for the real world..Trends Immunol2016;37:354-63PMC4885780

[225] Davis MMImmunology taught by humans..Sci Transl Med2012;4:117fs2

[226] Steinman RMResearch on human subjects in the JEM..J Exp Med2005;201:1349-50PMC2213194

[227] Hurez VSvatek RSConsiderations for successful cancer immunotherapy in aged hosts..Clin Exp Immunol2017;187:53-63PMC5167055

[228] Institute of Medicine (US)Sharing clinical research data: workshop summary..Washington (DC): National Academies Press (US);2013;

[229] Klinke DJ2ndA multiscale systems perspective on cancer, immunotherapy, and interleukin-12..Mol Cancer2010;9:242PMC3243044

[230] Palsson SBradshaw-Pierce ELJooss KSpilker MEVicini PThe development of a fully-integrated immune response model (FIRM) simulator of the immune response through integration of multiple subset models..BMC Syst Biol2013;7:95PMC3853972

[231] Narang VWong SYWasem ARGouaillard ASystems immunology: a survey of modeling formalisms, applications and simulation tools..Immunol Res2012;53:251-65

[232] Scharovsky OGRozados VRMetronomic chemotherapy: changing the paradigm that more is better..Curr Oncol2009;16:7-15PMC2669231

[233] Romiti ARoberto MCurrent achievements and future perspectives of metronomic chemotherapy..Invest New Drugs2017;35:359-74

[234] Dolgin EThe mathematician versus the malignancy..Nat Med2014;20:460-3

[235] Michor FImproving cancer treatment via mathematical modeling: surmounting the challenges is worth the effort..Cell2015;163:1059-63PMC4676401

[236] dePillis LGRadunskaya AEModeling cancer-immune responses to therapy..J Pharmacokinet Pharmacodyn2014;41:461-78

[237] Konstorum AAdler AJAddressing current challenges in cancer immunotherapy with mathematical and computational modelling..J R Soc Interface2017;14:20170150PMC5493798

[238] Radunskaya AModeling the kinetics of the immune response..In: d'Onofrio A, Cerrai P, Gandolfi A, editors. New challenges for cancer systems biomedicine.2012;MilanoSpringer Milan267-82

[239] Perelson ASImmunology for physicists..Rev Mod Phys1997;69:1219-68

[240] Stark JGeorge AJTOscillations in the immune system..Immunol Rev2007;216:213-31

[241] Transtrum MKBridging mechanistic and phenomenological models of complex biological systems..PLoS Comput Biol2016;12:e1004915PMC4871498

[242] Wenbo LUncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape..J R Soc Interface2017;14:20170105

[243] d'Onofrio AeditorsMathematical Oncology 2013..2014;New York, NYSpringer New York

[244] Molina-París CeditorsMathematical models and immune cell biology..2011;New York, NYSpringer New York

[245] Bassaganya-Riera JComputational immunology..2016;Cambridge, MAAcademic Press

[246] Kroer CSequential planning for steering immune system adaptation..2016;New York, USAAAAI Press/International Joint Conferences on Artificial Intelligence

[247] Sandholm T. Steering evolution strategically: computational game theory and opponent exploitation for treatment planning, drug design, and synthetic biology. 2015. Available from: https://www.aaai.org/ocs/index.php/AAAI/AAAI15/paper/view/10047. [Last accessed on 15 Dec 2017]

[248] Zhao YSocinski MAReinforcement learning strategies for clinical trials in nonsmall cell lung cancer..Biometrics2011;67:1422-33PMC3138840

[249] Wallace MPStephens DASMART thinking: a review of recent developments in sequential multiple assignment randomized trials..Curr Epidemiol Rep2016;3:225-32

[250] Littman DRreleasing the brakes on cancer immunotherapy..Cell2015;162:1186-90